Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

Summary

This phase II trial studies how well cemiplimab works in treating patients with nuclear protein of testis (NUT) carcinoma for which no treatment is currently available (incurable) and that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2025-08-15

Primary completion

2030-11-20

Completion

2035-11-20

Drugs

Indications